STOCK MARKET BSE NSE

JB Chemicals to buy Sanzyme probiotic brands for Rs 628 crore

Post the transaction JBCPL will become among the top five probiotics players in the country , in a segment that’s growing at around 12-14% . 

Published: 26th January 2022 11:09 PM  |   Last Updated: 26th January 2022 11:09 PM   |  A+A-

Salary, cash

Image used for representational purpose only.

By Express News Service

MUMBAI: JB Chemicals & Pharmaceuticals Ltd (JBCPL) will pay Rs 628 crore to acquire brands for the Indian market from Sanzyme, which is involved in the probiotics and reproductive health segment in the country . 

The transaction would be completed in the next two weeks , subject to customary closing formalities, the company send in an announcement to the stock exchanges . 

Post the transaction JBCPL will become among the top five probiotics players in the country , in a segment that’s growing at around 12-14% . 

“This acquisition reinforces our strategic intent to evaluate opportunities to supplement our growth ambition in India,” said Nikhil Chopra, CEO and whole-time director, JBCPL. 

The acquisition brands have a pan India presence and wide distribution reach of around three lakh chemists  and one lakh prescribers . The Sanzyme portfolio being acquired includes Sporlac, used for chronic kidney disease, and Oxalo, used to decalcify kidney stones. 

o3 advised Sanzyme for the transaction, whose value excludes related taxes, stamp duty and working capital . 

JBCPL is a leading player in the hypertension segment . Besides India, its other two home markets include Russia and South Africa . 

The stock of JBCPL closed flat at Rs 1728.55 on the BSE. The stock made a 52 week high /low of Rs 1984.75/Rs 957. The promoter of the company , Tau Investment Holdings has a 54% stake , with MFs holding 13.75% stake and FPIs 9.12% . 
 



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp